EP0155387A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Fibronolytically active hybrid protein, process for its preparation and pharmaceutical composition
Assignee: Beecham Group PLC
•
Filing: 1984-12-13
•
Granted: —
•
Expires: 2004-12-13
Abstract
Abstract A fibrinolytically active hybrid protein which comprises one chain of a 2-chain protease linked to a chain of a different 2-chain protease, or to the same chain of the same protease, at least one of the chains in the hybrid protein being derived from a fibrinolytically active protease, such that the hybrid protein has a catalytic site essential for fibrinolytic activity which is optionally blocked by a removable blocking group.
Inventors
- 👤 Jeffery Hugh Robinson
- 👤 Ian Dodd
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-26 13:10
CPC Classifications
C; C12; C12N; C12N9/00; C12N9/14; C12N9/48; C12N9/50; C12N9/64; C12N9/6421; C12N9/6424; C12N9/6435; C12N9/6456; C12N9/6459; C12Y; C12Y304/00; C12Y304/21; C12Y304/21007; C12Y304/21069; A; A61; A61K; A61K38/00; C07; C07K; C07K2319/00
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
71 words
1) A fibrinolytically active hybrid protein which comprises one chain of a 2-chain protease linked to a chain of a different 2-chain protease, or to the same chain of the same protease, at least one of the chains in the hybrid protein being derived from a fibrinolytically active protease, such that the hybrid protein has a catalytic site essential for fibrinolytic activity which is optionally blocked by a removable blocking group.
Claim 2
Dependent Claim
71 words
1) A fibrinolytically active hybrid protein which comprises one chain of a 2-chain protease linked to a chain of a different 2-chain protease, or to the same chain of the same protease, at least one of the chains in the hybrid protein being derived from a fibrinolytically active protease, such that the hybrid protein has a catalytic site essential for fibrinolytic activity which is optionally blocked by a removable blocking group.
Claim 3
Dependent Claim
24 words
2) A hybrid protein according to claim 1 comprising an A chain of one protease linked to the B chain of a different protease.
Claim 4
Dependent Claim
20 words
3) A hybrid protein according to claim 1 or claim 2 wherein at least one protease is a serine protease.
Claim 5
Dependent Claim
58 words
4) A hybrid protein according to any one of the preceding claims which comprises; plasmin A-chain linked to tissue plasminogen activator B-chain; tissue plasminogen activator A-chain linked to urokinase plasminogen activator B-chain; plasmin A-chain linked to urokinase plasminogen activator B-chain; tissue plasminogen activator A-chain linked to plasmin B-chain; or acylated plasmin A-chain linked to tissue plasminogen activator B-chain.
Claim 6
Dependent Claim
19 words
5) A hybrid protein according to claim 4 which comprises 4-aminobenzoyl plasmin A-chain linked to tissue plasminogen activator B-chain.
Claim 7
Dependent Claim
65 words
6) A process for the preparation of a hybrid protein according to any one of claims 1 to 5 which process comprises mixing a chain of one protease optionally blocked at an active site thereof with a chain of another protease also optionally blocked at an active site thereof under oxidative conditions; and thereafter if desired blocking any catalytic site with a removable blocking group.
Claim 8
Dependent Claim
13 words
7) A process according to claim 6 which is carried out under dialysis.
Claim 9
Dependent Claim
66 words
8) A process for preparing a hybrid protein according to any one of claims 1 to 5 which comprises taking the genetic information (DNA sequence) of each protein, cutting and ligating this to construct a new DNA sequence coding for the hybrid protein and expressing this DNA in a prokaryote or eurokaryote host; and thereafter if desired blocking the catalytic site with a removable blocking group.
Claim 10
Dependent Claim
21 words
9) A pharmaceutical composition comprising a fibrinolytally active hybrid protein according to claim 1 in combination with a pharmaceutically acceptable carrier.
Claim 11
Dependent Claim
18 words
10) A fibrinolytally active hybrid protein according to claim 1 for use in the treatment of thrombotic diseases.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.